CO6540003A2 - Inhibidor de bromodominio de benzodiazepina - Google Patents
Inhibidor de bromodominio de benzodiazepinaInfo
- Publication number
- CO6540003A2 CO6540003A2 CO12077201A CO12077201A CO6540003A2 CO 6540003 A2 CO6540003 A2 CO 6540003A2 CO 12077201 A CO12077201 A CO 12077201A CO 12077201 A CO12077201 A CO 12077201A CO 6540003 A2 CO6540003 A2 CO 6540003A2
- Authority
- CO
- Colombia
- Prior art keywords
- bromodominium
- benzodiazepina
- inhibitor
- condensed system
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un compuesto de benzodiazepina de la fórmula (I):a procesos para su preparación, a composiciones farmacéuticas que contienen este compuesto, y a su uso en terapia.Sector: compuestos heterociclicos que contienen átomos de nitrógeno como únicos heteroátomos del anillo en el sistema condensado, en los cuales el sistema condensado corresponde a un sistema orto condensado que contiene dos heteroanillos; composiciones medicinales que los contienen; útiles como agente antineoplásicos; fármacos para enfermedades inmunológicas o alérgicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0919433A GB0919433D0 (en) | 2009-11-05 | 2009-11-05 | Novel compounds |
GBGB1010509.6A GB201010509D0 (en) | 2010-06-22 | 2010-06-22 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6540003A2 true CO6540003A2 (es) | 2012-10-16 |
Family
ID=42667965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12077201A CO6540003A2 (es) | 2009-11-05 | 2012-05-10 | Inhibidor de bromodominio de benzodiazepina |
Country Status (32)
Country | Link |
---|---|
US (3) | US9023842B2 (es) |
EP (3) | EP2722334B1 (es) |
JP (1) | JP5524343B2 (es) |
KR (1) | KR101424989B1 (es) |
CN (1) | CN102762569B (es) |
AU (1) | AU2010314395B2 (es) |
BR (1) | BR112012010706A2 (es) |
CA (1) | CA2779355C (es) |
CL (1) | CL2012001178A1 (es) |
CO (1) | CO6540003A2 (es) |
CR (1) | CR20120283A (es) |
CY (2) | CY1114988T1 (es) |
DK (2) | DK2496580T3 (es) |
DO (1) | DOP2012000114A (es) |
EA (1) | EA020390B1 (es) |
ES (3) | ES2652304T3 (es) |
HK (3) | HK1191012A1 (es) |
HR (2) | HRP20140107T1 (es) |
HU (1) | HUE026421T2 (es) |
IL (2) | IL219090A0 (es) |
MA (1) | MA33803B1 (es) |
ME (1) | ME02360B (es) |
MX (1) | MX2012005295A (es) |
MY (1) | MY160456A (es) |
NZ (1) | NZ599258A (es) |
PE (1) | PE20121181A1 (es) |
PL (2) | PL2496580T3 (es) |
PT (2) | PT2496580E (es) |
RS (2) | RS53179B (es) |
SI (2) | SI2496580T1 (es) |
SM (2) | SMT201400024B (es) |
WO (1) | WO2011054553A1 (es) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102781943B (zh) * | 2009-11-05 | 2016-10-05 | 葛兰素史密丝克莱恩有限责任公司 | 苯并二氮杂*溴结构域抑制剂 |
GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
JP6022442B2 (ja) | 2010-05-14 | 2016-11-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 男性用避妊組成物および使用方法 |
MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
AU2011252808B2 (en) | 2010-05-14 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
DE102011082013A1 (de) * | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
CA2870931A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Isoindolone derivatives |
WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
AU2012382373A1 (en) | 2012-06-12 | 2014-12-11 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
RU2015102772A (ru) * | 2012-08-16 | 2016-10-10 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Бензодиазелипы для мелкоклеточного рака легкого |
PE20150729A1 (es) | 2012-08-16 | 2015-06-14 | Bayer Pharma AG | 2,3-benzodiazepines |
CA2886125A1 (en) | 2012-09-28 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Bet protein-inhibiting 5-aryl triazole azepines |
US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
CN105073744B (zh) | 2012-12-21 | 2019-11-08 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新型杂环化合物 |
US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
JP2016510039A (ja) * | 2013-02-28 | 2016-04-04 | ワシントン・ユニバーシティWashington University | ブロモドメイン阻害剤によるヒトサイトメガロウイルス感染および疾患の治療方法 |
EP2970262A1 (en) | 2013-03-11 | 2016-01-20 | AbbVie Inc. | Bromodomain inhibitors |
TW201444843A (zh) | 2013-03-11 | 2014-12-01 | Abbvie Inc | 溴區結構域蛋白抑制劑 |
EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
JP6280573B2 (ja) * | 2013-03-14 | 2018-02-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | ブロモドメイン阻害薬としてのフロピリジン |
US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
CA2903881C (en) | 2013-03-15 | 2021-05-18 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
EP2792355A1 (en) | 2013-04-17 | 2014-10-22 | Albert-Ludwigs-Universität Freiburg | Compounds for use as bromodomain inhibitors |
BR112015027130A2 (pt) | 2013-04-26 | 2018-07-24 | Beigene Ltd | 5-(3,5-dimetilisoxazol-4-il)indolin-2-ona substituído |
CA2915561C (en) | 2013-06-21 | 2020-09-22 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
WO2015002754A2 (en) | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
AR096758A1 (es) * | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
ES2635560T3 (es) | 2013-07-08 | 2017-10-04 | Incyte Holdings Corporation | Heterociclos tricíclicos como inhibidores de la proteína NET |
BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
CN105593224B (zh) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
US9428513B2 (en) | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
GB201320994D0 (en) * | 2013-11-28 | 2014-01-15 | Univ Dundee | Enzyme function probes |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
CN105940005A (zh) | 2014-01-31 | 2016-09-14 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
JP6526060B2 (ja) | 2014-02-10 | 2019-06-05 | コンサート ファーマシューティカルズ インコーポレイテッド | 置換トリアゾロベンゾジアゼピン |
EP3104845A4 (en) * | 2014-02-10 | 2017-09-27 | Salk Institute for Biological Studies | Increasing storage of vitamin a, vitamin d and/or lipids |
WO2015121230A1 (de) * | 2014-02-14 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | 9-substituierte 2,3-benzodiazepine |
RU2722179C2 (ru) | 2014-02-28 | 2020-05-28 | Тэнша Терапеутикс, Инк. | Лечение состояний, ассоциированных с гиперинсулинемией |
WO2015156601A1 (en) | 2014-04-09 | 2015-10-15 | Kainos Medicine, Inc. | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer |
NZ763737A (en) | 2014-04-23 | 2023-04-28 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
JP6682522B2 (ja) | 2014-06-20 | 2020-04-15 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. | 2−((4s)−6−(4−クロロフェニル)−1−メチル−4h−ベンゾ[c]イソオキサゾロ[4,5−e]アゼピン−4−イル)アセトアミドの結晶形態 |
NO2719005T3 (es) | 2014-07-28 | 2018-01-20 | ||
AU2015295405B2 (en) * | 2014-08-01 | 2020-04-09 | Nuevolution A/S | Compounds active towards bromodomains |
MX2017001757A (es) | 2014-08-08 | 2017-05-30 | Dana Farber Cancer Inst Inc | Derivados de dihidropteridinona y sus usos. |
MX2017001756A (es) | 2014-08-08 | 2017-05-30 | Dana Farber Cancer Inst Inc | Derivados de diazepano y sus usos. |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
RU2697393C2 (ru) * | 2014-10-02 | 2019-08-14 | ГлаксоСмитКлайн Интеллекчуал Проперти (N 2) Лимитед | Кристаллическая твердая форма соли бензолсульфоновой кислоты и 2-[(4S)-6-(4-хлорфенил)-1-метил-8-(метилокси)-4H-[1,2,4]триазоло[4,3-a][1,4]бензодиазепин-4-ил]-N-этилацетамида, способ ее получения и фармацевтическая композиция, содержащая ее |
EP3212654B1 (en) | 2014-10-27 | 2020-04-08 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
US10813939B2 (en) | 2014-12-05 | 2020-10-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
WO2016097863A1 (en) | 2014-12-17 | 2016-06-23 | Zenith Epigenetics Corp. | Inhibitors of bromodomains |
EP3253756B1 (en) | 2015-02-03 | 2021-09-22 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
JP2018520124A (ja) | 2015-06-26 | 2018-07-26 | テンシャ セラピューティクス,インコーポレイテッド | Nut正中線癌の治療 |
JP6765622B2 (ja) | 2015-07-17 | 2020-10-07 | 日本光電工業株式会社 | 救命支援装置 |
RU2750164C2 (ru) | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Цианотиенотриазолодиазепины и пути их применения |
UA123946C2 (uk) | 2015-09-11 | 2021-06-30 | Дана-Фарбер Кенсер Інстітьют, Інк. | Ацетамідтієнотриазолодіазепіни й шляхи їх застосування |
CN108289957A (zh) * | 2015-10-02 | 2018-07-17 | 达纳-法伯癌症研究所股份有限公司 | 溴区结构域抑制剂和检查点阻断的组合疗法 |
WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
WO2017091673A2 (en) | 2015-11-25 | 2017-06-01 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibtors and uses thereof |
MX2018012541A (es) | 2016-04-15 | 2019-01-17 | Abbvie Inc | Inhibidores de bromodominios. |
US10189832B2 (en) | 2016-06-20 | 2019-01-29 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
WO2018022802A1 (en) | 2016-07-26 | 2018-02-01 | University Of Southern California | Selective bromodomain inhibition of fungal bdf1 |
US20190284192A1 (en) | 2016-11-10 | 2019-09-19 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
CN107759607B (zh) * | 2017-11-29 | 2019-08-23 | 上海万巷制药有限公司 | 具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法 |
MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
TW202219056A (zh) | 2020-06-23 | 2022-05-16 | 美商建南德克公司 | 巨環化合物及其使用方法 |
GB202016977D0 (en) | 2020-10-26 | 2020-12-09 | In4Derm Ltd | Compounds |
US20230357240A1 (en) | 2020-12-01 | 2023-11-09 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Novel n-heterocyclic bet bromodomain inhibitor, and preparation method thereof and medical use thereof |
CA3224302A1 (en) | 2021-06-29 | 2023-01-05 | Tay Therapeutics Limited | Pyrrolopyridone derivatives useful in the treatment of cancer |
WO2023205251A1 (en) | 2022-04-19 | 2023-10-26 | Nuevolution A/S | Compounds active towards bromodomains |
WO2024018423A1 (en) | 2022-07-21 | 2024-01-25 | Tay Therapeutics Limited | Pyrroles and imidazoles as bet protein inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3610848A1 (de) * | 1986-04-01 | 1987-10-15 | Boehringer Ingelheim Kg | Neue 1,4-diazepine |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
CA2120939A1 (en) | 1991-10-11 | 1993-04-15 | Tetsuya Tahara | Therapeutic agent for osteoporosis and diazepine compound |
JPH06128257A (ja) | 1992-10-13 | 1994-05-10 | Yoshitomi Pharmaceut Ind Ltd | ピリドジアゼピン化合物 |
JP2840454B2 (ja) | 1993-11-22 | 1998-12-24 | メルク エンド カンパニー インコーポレーテッド | ベンゾジアゼピン類 |
IT1285567B1 (it) | 1996-02-21 | 1998-06-18 | Alfa Chem Ital | Nuovo processo per la sintesi del nabumetone |
IL127516A0 (en) * | 1996-06-12 | 1999-10-28 | Japan Tobacco Inc | A cytokine production inhibitor |
WO1998011111A1 (fr) | 1996-09-13 | 1998-03-19 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de thienotriazolodiazepine et leurs utilisations a des fins medicinales |
JPH11228576A (ja) * | 1997-12-10 | 1999-08-24 | Japan Tobacco Inc | アポトーシス抑制剤 |
JP4641526B2 (ja) | 2003-11-03 | 2011-03-02 | グラクソ グループ リミテッド | 流体分配デバイス |
SG115845A1 (en) | 2004-03-31 | 2005-10-28 | Univ Singapore | Modulation of trip-br function and method of treating proliferative disorders |
GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Brd2ブロモドメイン結合剤 |
CN101910182B (zh) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
-
2010
- 2010-08-06 DK DK10740654.8T patent/DK2496580T3/da active
- 2010-08-06 EP EP13192666.9A patent/EP2722334B1/en active Active
- 2010-08-06 RS RS20140088A patent/RS53179B/en unknown
- 2010-08-06 MY MYPI2012001967A patent/MY160456A/en unknown
- 2010-08-06 PE PE2012000614A patent/PE20121181A1/es not_active Application Discontinuation
- 2010-08-06 HU HUE13192666A patent/HUE026421T2/en unknown
- 2010-08-06 WO PCT/EP2010/061518 patent/WO2011054553A1/en active Application Filing
- 2010-08-06 SI SI201030514T patent/SI2496580T1/sl unknown
- 2010-08-06 CA CA2779355A patent/CA2779355C/en not_active Expired - Fee Related
- 2010-08-06 US US13/505,039 patent/US9023842B2/en active Active
- 2010-08-06 ES ES16150637.3T patent/ES2652304T3/es active Active
- 2010-08-06 AU AU2010314395A patent/AU2010314395B2/en not_active Ceased
- 2010-08-06 PT PT107406548T patent/PT2496580E/pt unknown
- 2010-08-06 ME MEP-2016-53A patent/ME02360B/me unknown
- 2010-08-06 PL PL10740654T patent/PL2496580T3/pl unknown
- 2010-08-06 MX MX2012005295A patent/MX2012005295A/es active IP Right Grant
- 2010-08-06 EA EA201290183A patent/EA020390B1/ru not_active IP Right Cessation
- 2010-08-06 PT PT131926669T patent/PT2722334E/pt unknown
- 2010-08-06 PL PL13192666T patent/PL2722334T3/pl unknown
- 2010-08-06 EP EP16150637.3A patent/EP3037423B1/en active Active
- 2010-08-06 ES ES10740654.8T patent/ES2446647T3/es active Active
- 2010-08-06 RS RS20160102A patent/RS54592B1/en unknown
- 2010-08-06 KR KR1020127014637A patent/KR101424989B1/ko active IP Right Grant
- 2010-08-06 SI SI201031117T patent/SI2722334T1/sl unknown
- 2010-08-06 DK DK13192666.9T patent/DK2722334T3/en active
- 2010-08-06 CN CN201080050285.XA patent/CN102762569B/zh not_active Expired - Fee Related
- 2010-08-06 ES ES13192666.9T patent/ES2563057T3/es active Active
- 2010-08-06 NZ NZ599258A patent/NZ599258A/en not_active IP Right Cessation
- 2010-08-06 EP EP10740654.8A patent/EP2496580B1/en active Active
- 2010-08-06 JP JP2012537329A patent/JP5524343B2/ja active Active
- 2010-08-06 BR BR112012010706A patent/BR112012010706A2/pt active Search and Examination
-
2012
- 2012-04-05 IL IL219090A patent/IL219090A0/en unknown
- 2012-04-18 DO DO2012000114A patent/DOP2012000114A/es unknown
- 2012-05-04 CL CL2012001178A patent/CL2012001178A1/es unknown
- 2012-05-10 CO CO12077201A patent/CO6540003A2/es unknown
- 2012-05-28 CR CR20120283A patent/CR20120283A/es unknown
- 2012-06-04 MA MA34934A patent/MA33803B1/fr unknown
-
2013
- 2013-02-21 HK HK14104251.0A patent/HK1191012A1/zh not_active IP Right Cessation
- 2013-02-21 HK HK13102225.8A patent/HK1175458A1/xx not_active IP Right Cessation
-
2014
- 2014-02-05 HR HRP20140107AT patent/HRP20140107T1/hr unknown
- 2014-02-18 CY CY20141100124T patent/CY1114988T1/el unknown
- 2014-02-20 SM SM201400024T patent/SMT201400024B/xx unknown
- 2014-11-30 IL IL235983A patent/IL235983B/en active IP Right Grant
-
2015
- 2015-04-13 US US14/684,659 patent/US20150210706A1/en not_active Abandoned
-
2016
- 2016-02-03 HR HRP20160119TT patent/HRP20160119T1/hr unknown
- 2016-03-01 CY CY20161100172T patent/CY1117479T1/el unknown
- 2016-03-22 SM SM201600081T patent/SMT201600081B/xx unknown
- 2016-07-13 HK HK16108220.7A patent/HK1220188A1/zh unknown
-
2017
- 2017-01-20 US US15/410,874 patent/US20170197972A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6540003A2 (es) | Inhibidor de bromodominio de benzodiazepina | |
DOP2012000310A (es) | Morfolinopirimidinas y su uso en terapia | |
AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
CR20180339A (es) | INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576) | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
GT201300137A (es) | Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
UY30759A1 (es) | Compuestos quimicos | |
DOP2010000259A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211 | |
UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
UY31639A1 (es) | Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones | |
CR20120634A (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
CR20140144A (es) | Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
CR20150007A (es) | Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
UY31864A (es) | Derivados de urea hetericíclica y métodos de uso de los mismos-332 | |
UY32856A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
UY32694A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
EA201591175A1 (ru) | Трициклические соединения в качестве ингибиторов cftr | |
CL2012001641A1 (es) | Compuestos derivados de piperazina; composición farmacéutica; que comprende a uno de los compuestos y uso de los compuestos en la preparación de medicamentos para el tratamiento y/o prevención de infecciones por protozoos, en forma particular para el tratamiento y/o prevención de la malaria. | |
ECSP13012372A (es) | Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. | |
AR125187A2 (es) | PIRIMIDINIL Y 1,3,5-TRIACINIL BENCIMIDAZOLES (ARALQUILAMINO Y HETEROARILALQUILAMINO SUSTITUIDOS EN a), SUS COMPOSICIONES FARMACÉUTICAS, Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS |